atracurium besilate kalceks
as kalceks - atrakurio besilatas - injekcinis ar infuzinis tirpalas - 10 mg/ml - atracurium
cisatracurium accord
accord healthcare b.v. - cisatrakuris - injekcinis ar infuzinis tirpalas - 5 mg/ml; 2 mg/ml - cisatracurium
cisatracurium kabi
fresenius kabi polska sp.z.o.o. - cisatrakuris - injekcinis ar infuzinis tirpalas - 2 mg/ ml; 5 mg/ml - cisatracurium
cisatracurium kalceks
as kalceks - cisatrakuris - injekcinis ar infuzinis tirpalas - 2 mg/ml - cisatracurium
cisatracurium norameda
norameda, uab - cisatrakuris - injekcinis ar infuzinis tirpalas - 2 mg/ml - cisatracurium
atracurium hikma
edupharma, uab - atrakurio besilatas - injekcinis ar infuzinis tirpalas - 10 mg/ml - atracurium
atracurium kalceks
adeofarma, uab - atrakurio besilatas - injekcinis ar infuzinis tirpalas - 10 mg/ml - atracurium
cisatracurium hameln
limedika, uab - cisatrakuris - injekcinis ar infuzinis tirpalas - 2 mg/ml - cisatracurium
fludeomap
curium finland oy - fludeoksigliukozė (18f) - injekcinis tirpalas - 250 mbq/ml - fludeoxyglucose (18f)
pylclari
curium pet france - piflufolastat (18f) - prostatos navikai - diagnostikos radiofarmaciniai preparatai - Šis vaistas yra skirtas tik diagnostikai. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).